Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | GLA | P06280 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR4 | P51679 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643096 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL27808555 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL3636285 | 0.79 | KDM4E (0.74) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL30896243 | 0.79 | CCR4 (0.73) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL11743074 | 0.79 | CCR4 (0.73) | KDM4EALDH1A1NPSR1LMNAHTT | |
| Hydrochloric Acid SCHEMBL11772393 | 0.78 | KDM4E (0.72) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL3639295 | 0.75 | HTT (0.59) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL14941378 | 0.73 | DNMT3A (0.68) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL2592612 | 0.73 | PDE5A (1.00) | KDM4EALDH1A1NPSR1LMNAHTT | |
| SCHEMBL2590824 | 0.73 | HTR2A (0.84) | KDM4EALDH1A1NPSR1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | KDM4E 3866/4885ALDH1A1 2522/4885NPSR1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.